

SOURCE: Neptune Technologies & Bioresources Inc.

Neptune Reports on Preliminary 2011 Year End Results

Laval, Québec, CANADA – March 22nd, 2011 – Neptune Technologies & Bioresources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) provides guidance for the expected financial results of the fiscal 2011 fourth quarter and fiscal year ended February 28, 2011.

Neptune Preliminary Financial Results

Neptune expects nutraceutical business revenues for the fourth quarter ended February 28, 2011 in the range of \$4,000,000 to \$4,200,000.

Nutraceutical business revenues for the fiscal year ended February 28, 2011 are expected to be in the range of \$16,500,000 to \$16,800,000, compared to \$12,605,587 for the corresponding twelve-month period ended February 28, 2010. This represents an increase of 31% to 33%. “We also increased our production capacity by more than 100% over the last 18 months, which represents the most significant increase in Neptune’s history,” stated Frederic Harland, Director, Finance of Neptune.

“Despite the increasing competitiveness of the market and the negative impact of the fluctuation of the Canadian dollar versus the US dollar, we increased our revenues by more than 30%, which would represent our most important revenue increase in the past five (5) years,” added Andre Godin, CFO of Neptune.

[About Neptune Technologies & Bioresources Inc.](#)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 20 countries worldwide.

[About Acasti Pharma Inc.](#)

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

[About NeuroBioPharm Inc.](#)

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Neptune Contact:

Neptune Technologies & Bioresources Inc.
André Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com

CEOcast Contact:

Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com

Howard Group Contact:

Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com

###

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.